Lisa J Edelmann, PhD
img_Lisa J Edelmann
ASSOCIATE PROFESSOR | Genetics and Genomic Sciences

The molecular genetics laboratory is focused on the detection of carriers for specific genetic diseases.  In particular, the laboratory has been a leading provider of genetic testing for the Ashkenazi Jewish (AJ) community living in the greater New York metropolitan area.  This population is at increased risk for a number of autosomal recessive diseases that are lethal in childhood or are associated with significant mental or physical disability.  These diseases generally have a limited number of specific mutations and are present in greater than 95 persent of affected patients, due to genetic drift and/or selection.  The laboratory also offers pre- and postnatal mutation scanning for Noonan syndrome.  In addition, we have recently validated a panel of cytochrome P450 variants for the detection of individuals with genotypes that may require dosage adjustments for specific medications.  Research in the laboratory is focused on population screening of Ashkenazi Jewish samples to accurately determine carrier frequencies and allele distributions and assess whether certain mutations or variations may confer increased risk for specific adult-onset diseases.

The molecular cytogenetics laboratory offers Fluorescence in Situ Hybridization (FISH) for a number of chromosome rearrangement disorders, including DiGeorge syndrome, Williams syndrome, Prader Willi and Angelman syndromes, Wolf-Hirschhorn syndrome Cri-du-Chat syndrome, Smith Magenis syndrome and Miller-Dieker syndrome.  We are currently developing testing panels using multiplex ligation-dependent probe amplification (MLPA) and targeted array CGH (Comparative Genomic Hybridization) to increase our ability to clinically detect rearrangements that are not visible by standard karyotype analysis but involve genomic copy number changes. Research in the molecular cytogenetics laboratory is focused on chromosome rearrangement disorders and their mechanism of generation. Most chromosome rearrangements occur sporadically in the population at a specific frequency, depending on the disorder. The combined frequency of chromosome rearrangements, balanced and unbalanced, including translocations, deletions, duplications and inversions is estimated at 1 in 300 live births. For many of these disorders, genomic architecture plays an important role in susceptibility to rearrangement. We are currently investigating the mechanism that generates the isodicentric Xq chromosome (idic(Xq)), a spontaneously occurring chromosomal aberration that is present in 18 percent of Turner Syndrome cases, and is the most common constitutional isochromosome in humans. We have collected a number of cell lines to delineate the breakpoints of the idic(Xq) in order to better understand how the architecture in the region of Xp11 influences formation of the isochromosome.  Our methods of study include FISH and array CGH, generation of human hamster somatic hybrid cell lines, pulse field gel electrophoresis and long range PCR to amplify across breakpoint junctions. Ultimately, we would like to determine whether specific variations in genomic architecture at the breakpoint regions of recurrent rearrangements confer increased susceptibility to the rearrangement.The laboratory is also involved in a collaborative effort to understand how chromosome rearrangement disorders contribute to autism by investigating the frequency of known micro- deletion and duplication syndromes in autism patients as well as delineating novel de novo rearrangements in autism.

Albert Einstein College of Medicine

Albert Einstein College of Medicine

Mount Sinai School of Medicine


Selected Publications

Molecular diagnostic yield of genome sequencing versus targeted gene panel testing in racially and ethnically diverse pediatric patients. Noura S. Abul-Husn, Priya N. Marathe, Nicole R. Kelly, Katherine E. Bonini, Monisha Sebastin, Jacqueline A. Odgis, Avinash Abhyankar, Kaitlyn Brown, Miranda Di Biase, Katie M. Gallagher, Saurav Guha, Nicolette Ioele, Volkan Okur, Michelle A. Ramos, Jessica E. Rodriguez, Atteeq U. Rehman, Amanda Thomas-Wilson, Lisa Edelmann, Randi E. Zinberg, George A. Diaz, John M. Greally, Vaidehi Jobanputra, Sabrina A. Suckiel, Carol R. Horowitz, Melissa P. Wasserstein, Eimear E. Kenny, Bruce D. Gelb. Genetics in Medicine

Clinical Pharmacogenomic MT-RNR1 Screening for Aminoglycoside-Induced Ototoxicity and the Post-Test Counseling Conundrum. Robert Rigobello, Jay Shaw, Daniel Ilg, Rebekah Zimmerman, Lisa Edelmann, Ruth Kornreich, Stuart A. Scott, Neal Cody. Clinical Pharmacology and Therapeutics

Identification of copy number variants with genome sequencing: Clinical experiences from the NYCKidSeq program. Katherine E. Bonini, Amanda Thomas-Wilson, Priya N. Marathe, Monisha Sebastin, Jacqueline A. Odgis, Miranda Di Biase, Nicole R. Kelly, Michelle A. Ramos, Beverly J. Insel, Laura Scarimbolo, Atteeq U. Rehman, Saurav Guha, Volkan Okur, Avinash Abhyankar, Shruti Phadke, Caroline Nava, Katie M. Gallagher, Lama Elkhoury, Lisa Edelmann, Randi E. Zinberg, Noura S. Abul-Husn, George A. Diaz, John M. Greally, Sabrina A. Suckiel, Carol R. Horowitz, Eimear E. Kenny, Melissa Wasserstein, Bruce D. Gelb, Vaidehi Jobanputra. Clinical Genetics

View All Publications

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Dr. Edelmann has not yet completed reporting of Industry relationships.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.